Comparing the current results to its competitors, Reata Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2023 by 2885.04 % year on year. The sales growth was above Reata Pharmaceuticals Inc 's competitors' average revenue growth of 2.95 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 2885.04 % Reata Pharmaceuticals Inc improved its market share, to approximately 0.05 %.
Publicly Traded Peers of Reata Pharmaceuticals Inc
Inflarx N V Share Performance
+25.99%
30 Days
Inflarx N V
Profile
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Intercept Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics in the field of chronic liver diseases. Their business model revolves around identifying and targeting specific liver diseases with high unmet medical needs, conducting extensive research and clinical trials to develop effective therapies, and then commercializing these drugs globally to generate sustainable revenue streams. By addressing liver diseases with innovative treatments, Intercept aims to improve patient outcomes and establish a profitable position in the pharmaceutical industry.
Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company's business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc's efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Deciphera Pharmaceuticals Inc's business model revolves around the research, development, and commercialization of precision medicines for the treatment of cancer and other serious diseases.
Sources:
Reata Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Reata Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
